ZTS
Zoetis Inc. NYSE Listed Feb 1, 2013$87.36
After hrs
$82.85
+0.02%
Mkt Cap $36.9B
52w Low $85.32
2.3% of range
52w High $172.23
50d MA $118.92
200d MA $131.66
P/E (TTM)
18.9x
EV/EBITDA
15.5x
P/B
15.2x
Debt/Equity
2.9x
ROE
80.2%
P/FCF
24.4x
RSI (14)
—
ATR (14)
—
Beta
0.97
50d MA
$118.92
200d MA
$131.66
Avg Volume
4.1M
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
10 Sylvan Way · Parsippany, NJ 07054 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | TNS | 1.60 | 1.53 | -4.4% | — | — | — | — | — | — | — | — |
| Feb 12, 2026 | TNS | 1.40 | 1.48 | +5.7% | 125.64 | +0.8% | +0.8% | -0.1% | +2.8% | +1.3% | +2.5% | — |
| Nov 4, 2025 | TNS | 1.62 | 1.70 | +4.9% | 124.46 | -0.2% | -3.2% | -3.9% | -3.4% | -3.8% | -3.5% | — |
| Aug 5, 2025 | TNS | 1.62 | 1.76 | +8.6% | 146.12 | +0.1% | +0.3% | +1.5% | +0.8% | +2.0% | +2.5% | — |
| May 6, 2025 | TNS | 1.41 | 1.48 | +5.0% | 149.87 | +1.2% | +4.1% | +7.9% | +6.3% | +8.0% | +7.0% | — |
| Feb 13, 2025 | TNS | 1.37 | 1.40 | +2.2% | 164.93 | -0.6% | -4.5% | -5.1% | -5.0% | -4.6% | -2.7% | — |
| Nov 4, 2024 | TNS | 1.46 | 1.58 | +8.2% | 175.18 | -0.4% | +0.1% | -2.7% | -0.5% | +0.9% | +0.6% | — |
| Aug 6, 2024 | TNS | 1.49 | 1.56 | +4.7% | 185.29 | +0.4% | -0.3% | +1.6% | -0.0% | -0.8% | +1.7% | — |
| May 2, 2024 | TNS | 1.34 | 1.38 | +3.0% | 167.23 | +1.9% | -0.1% | -0.8% | +0.7% | -1.4% | +0.5% | — |
| Feb 13, 2024 | TNS | 1.32 | 1.24 | -6.1% | 183.49 | +0.9% | +0.3% | +3.4% | +2.7% | +1.7% | +2.7% | — |
| Nov 2, 2023 | TNS | 1.36 | 1.36 | +0.0% | 160.91 | +2.1% | +0.8% | +1.4% | +3.9% | +6.2% | +6.0% | — |
| Aug 8, 2023 | TNS | 1.32 | 1.41 | +6.8% | 189.30 | +0.3% | +0.0% | -0.1% | +0.8% | +0.2% | -0.1% | — |
| May 4, 2023 | AMC | 1.26 | 1.31 | +4.0% | 178.47 | +0.9% | +4.3% | +3.6% | +3.3% | +3.7% | +3.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $117.87 | $117.23 | -0.5% | -1.0% | -3.4% | -2.5% | -3.1% | -4.4% |
| Feb 13 | BofA Securities | Maintains | Neutral → Neutral | — | $125.64 | $126.67 | +0.8% | +0.8% | -0.1% | +2.8% | +1.3% | +2.5% |
| Jan 22 | Piper Sandler | Downgrade | Overweight → Neutral | — | $125.08 | $124.27 | -0.6% | -0.5% | -0.8% | -0.9% | -0.1% | -2.5% |
| Dec 3 | BTIG | Maintains | Buy → Buy | — | $124.44 | $125.28 | +0.7% | -1.5% | -3.2% | -4.7% | -5.0% | -7.0% |
| Nov 18 | Stifel | Maintains | Hold → Hold | — | $118.80 | $118.43 | -0.3% | -0.6% | -1.4% | -2.4% | +2.7% | +3.4% |
| Nov 12 | BTIG | Maintains | Buy → Buy | — | $120.12 | $120.18 | +0.1% | +0.9% | +0.9% | +0.6% | -1.1% | -1.6% |
| Nov 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $120.24 | $120.43 | +0.2% | -0.4% | -0.1% | +0.8% | +0.8% | +0.5% |
| Nov 5 | UBS | Maintains | Neutral → Neutral | — | $124.46 | $124.20 | -0.2% | -3.2% | -3.9% | -3.4% | -3.8% | -3.5% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $124.46 | $124.20 | -0.2% | -3.2% | -3.9% | -3.4% | -3.8% | -3.5% |
| Oct 20 | UBS | Maintains | Neutral → Neutral | — | $144.06 | $143.87 | -0.1% | +0.7% | +1.4% | +2.1% | +1.6% | +1.3% |
| Sep 9 | Argus | Maintains | Buy → Buy | — | $151.75 | $151.41 | -0.2% | -1.3% | -1.5% | -0.8% | -2.3% | -3.6% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $147.35 | $147.67 | +0.2% | +1.1% | +1.6% | +3.5% | +3.9% | +4.6% |
| Jul 17 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $151.54 | $150.00 | -1.0% | -1.0% | -1.9% | -2.8% | -0.2% | +1.3% |
| Jun 18 | Stifel | Downgrade | Buy → Hold | — | $161.67 | $157.09 | -2.8% | -4.1% | -2.8% | -2.7% | -2.4% | -2.7% |
| May 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $159.27 | $161.03 | +1.1% | +1.7% | +0.7% | -2.7% | +0.7% | +2.4% |
| May 7 | UBS | Maintains | Neutral → Neutral | — | $149.87 | $151.68 | +1.2% | +4.1% | +7.9% | +6.3% | +8.0% | +7.0% |
| Apr 14 | Stifel | Maintains | Buy → Buy | — | $149.44 | $151.46 | +1.4% | +0.9% | -0.1% | -1.8% | -0.5% | -1.7% |
| Feb 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $164.99 | $164.60 | -0.2% | -0.0% | +1.4% | +3.4% | +3.0% | +1.2% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $164.93 | $163.98 | -0.6% | -4.5% | -5.1% | -5.0% | -4.6% | -2.7% |
| Feb 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $164.93 | $163.98 | -0.6% | -4.5% | -5.1% | -5.0% | -4.6% | -2.7% |
| Feb 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $171.43 | $171.43 | +0.0% | +0.3% | +1.7% | +1.4% | -3.8% | -8.1% |
| Jan 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $170.42 | $169.70 | -0.4% | -0.1% | +1.3% | +0.3% | +0.9% | +1.1% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $165.90 | $163.20 | -1.6% | -1.5% | -0.5% | -1.6% | +0.3% | -0.9% |
| Oct 11 | JP Morgan | Maintains | Overweight → Overweight | — | $190.28 | $190.21 | -0.0% | -0.1% | +1.2% | +1.1% | +2.2% | +0.4% |
| Sep 18 | Stifel | Maintains | Buy → Buy | — | $195.71 | $196.80 | +0.6% | +0.4% | -1.3% | -1.6% | -1.1% | -1.0% |
| Aug 27 | Stifel | Maintains | Buy → Buy | — | $181.56 | $181.98 | +0.2% | +0.3% | +0.7% | +0.7% | +1.1% | +1.1% |
| Aug 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $188.38 | $188.05 | -0.2% | -2.7% | -2.3% | -2.5% | -2.1% | -2.5% |
| Aug 12 | BTIG | Maintains | Buy → Buy | — | $185.25 | $184.86 | -0.2% | -0.8% | +1.7% | -1.0% | -0.6% | -0.8% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $185.29 | $186.00 | +0.4% | -0.3% | +1.6% | -0.0% | -0.8% | +1.7% |
| Aug 5 | Stifel | Maintains | Buy → Buy | — | $180.59 | $176.18 | -2.4% | -3.2% | +2.6% | +2.3% | +4.3% | +2.6% |
| May 8 | HSBC | Maintains | Buy → Buy | — | $168.45 | $167.08 | -0.8% | -2.1% | -0.2% | +0.4% | -0.3% | +0.2% |
| May 6 | Goldman Sachs | Maintains | Buy → Buy | — | $167.07 | $167.35 | +0.2% | -0.7% | +0.8% | -1.3% | +0.6% | +1.2% |
| Apr 30 | Stifel | Maintains | Buy → Buy | — | $159.70 | $159.64 | -0.0% | -0.3% | -0.8% | +4.7% | +4.6% | +3.9% |
| Apr 23 | Barclays | Maintains | Overweight → Overweight | — | $145.54 | $146.25 | +0.5% | +2.8% | +3.7% | +5.4% | +8.8% | +9.7% |
| Apr 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $149.77 | $150.20 | +0.3% | +2.2% | +1.4% | +2.2% | -2.2% | -2.8% |
| Apr 2 | Stifel | Maintains | Buy → Buy | — | $167.02 | $165.67 | -0.8% | -1.2% | -2.4% | -0.9% | -0.7% | -0.8% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $188.39 | $187.30 | -0.6% | -1.0% | -0.0% | +4.4% | +4.7% | +4.6% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $183.49 | $185.19 | +0.9% | +0.3% | +3.4% | +2.7% | +1.7% | +2.7% |
| Jan 17 | Goldman Sachs | Maintains | Buy → Buy | — | $192.99 | $191.99 | -0.5% | -1.1% | -1.3% | -2.4% | -0.9% | -2.5% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $162.23 | $170.28 | +5.0% | +0.6% | +3.0% | +5.3% | +5.2% | +4.4% |
| Oct 30 | Stifel | Maintains | Buy → Buy | — | $156.03 | $157.13 | +0.7% | +0.6% | +0.6% | -2.9% | +3.1% | +4.0% |
| Sep 12 | Stifel | Maintains | Buy → Buy | — | $186.07 | $185.23 | -0.5% | +0.9% | -2.2% | -1.8% | -3.1% | -3.5% |
| Aug 28 | Stifel | Maintains | Buy → Buy | — | $182.82 | $184.51 | +0.9% | +2.3% | +5.4% | +5.4% | +4.2% | +5.3% |
| Aug 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $190.83 | $190.21 | -0.3% | -0.6% | -0.9% | -2.4% | -4.2% | -4.9% |
| Aug 10 | Goldman Sachs | Maintains | Buy → Buy | — | $189.35 | $190.00 | +0.3% | -0.1% | +0.8% | +0.2% | -0.1% | -1.6% |
| Jun 14 | Atlantic Equities | Maintains | Overweight → Overweight | — | $166.01 | $167.08 | +0.6% | -0.2% | +3.3% | +2.8% | +1.7% | +2.3% |
| May 26 | Atlantic Equities | Maintains | Overweight → Overweight | — | $165.24 | $165.66 | +0.3% | -0.3% | -2.6% | -1.3% | +0.5% | +4.0% |
| May 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $186.23 | $186.31 | +0.0% | -0.7% | -1.0% | -0.6% | -0.6% | -1.4% |
| Feb 21 | Barclays | Maintains | Overweight → Overweight | — | $172.03 | $171.53 | -0.3% | -1.3% | -3.3% | -1.5% | -3.3% | -3.8% |
| Nov 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $146.45 | $149.70 | +2.2% | +2.3% | +1.2% | -1.9% | -0.6% | +0.6% |
No insider trades available.
8-K
ZOETIS INC. -- 8-K Filing
Zoetis reported Q4 and full-year 2025 results and issued 2026 guidance, providing investors with updated financial performance metrics and forward-looking expectations for the animal health company.
Feb 12
8-K · 7.01
! Medium
ZOETIS INC. -- 8-K 7.01: Regulation FD Disclosure
Zoetis declared a $0.53 per share dividend payable June 2, 2026, to shareholders of record April 20, 2026, providing steady income returns to investors.
Feb 5
Data updated apr 27, 2026 11:51am
· Source: massive.com